vs
Creative Media & Community Trust Corp（CMCT）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
REGENXBIO Inc.的季度营收约是Creative Media & Community Trust Corp的1.1倍（$30.3M vs $28.5M），Creative Media & Community Trust Corp净利率更高（-125.8% vs -221.3%，领先95.6%），REGENXBIO Inc.同比增速更快（43.0% vs 3.6%），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -8.5%）
Creative Media & Community Trust Corp是一家总部位于美国的房地产投资信托企业，核心运营两大板块：持有、管理及开发专业影视制作工作室等创意媒体设施，以及经济适用房、社区医疗中心、邻里商业空间等民生类物业，服务传媒客户及各地社区居民。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
CMCT vs RGNX — 直观对比
营收规模更大
RGNX
是对方的1.1倍
$28.5M
营收增速更快
RGNX
高出39.4%
3.6%
净利率更高
CMCT
高出95.6%
-221.3%
两年增速更快
RGNX
近两年复合增速
-8.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $28.5M | $30.3M |
| 净利润 | $-11.4M | $-67.1M |
| 毛利率 | — | — |
| 营业利润率 | -125.6% | -190.0% |
| 净利率 | -125.8% | -221.3% |
| 营收同比 | 3.6% | 43.0% |
| 净利润同比 | -11.4% | -31.2% |
| 每股收益（稀释后） | $-3.89 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CMCTRGNX
| Q4 25 | $28.5M | $30.3M | ||
| Q3 25 | $26.2M | $29.7M | ||
| Q2 25 | $29.7M | $21.4M | ||
| Q1 25 | $32.3M | $89.0M | ||
| Q4 24 | $27.5M | $21.2M | ||
| Q3 24 | $28.6M | $24.2M | ||
| Q2 24 | $34.4M | $22.3M | ||
| Q1 24 | $34.0M | $15.6M |
净利润CMCTRGNX
| Q4 25 | $-11.4M | $-67.1M | ||
| Q3 25 | $-12.5M | $-61.9M | ||
| Q2 25 | $-9.0M | $-70.9M | ||
| Q1 25 | $-6.1M | $6.1M | ||
| Q4 24 | $-10.3M | $-51.2M | ||
| Q3 24 | $-10.4M | $-59.6M | ||
| Q2 24 | $-796.0K | $-53.0M | ||
| Q1 24 | $-3.7M | $-63.3M |
毛利率CMCTRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 70.2% | ||
| Q3 24 | — | 48.8% | ||
| Q2 24 | — | 52.5% | ||
| Q1 24 | — | 72.6% |
营业利润率CMCTRGNX
| Q4 25 | -125.6% | -190.0% | ||
| Q3 25 | -47.7% | -176.3% | ||
| Q2 25 | -30.3% | -296.3% | ||
| Q1 25 | -19.0% | 13.6% | ||
| Q4 24 | -128.8% | -242.1% | ||
| Q3 24 | -36.9% | -256.6% | ||
| Q2 24 | -1.6% | -251.3% | ||
| Q1 24 | -10.7% | -408.8% |
净利率CMCTRGNX
| Q4 25 | -125.8% | -221.3% | ||
| Q3 25 | -47.5% | -208.3% | ||
| Q2 25 | -30.3% | -331.8% | ||
| Q1 25 | -18.9% | 6.8% | ||
| Q4 24 | -129.8% | -241.3% | ||
| Q3 24 | -36.3% | -246.3% | ||
| Q2 24 | -2.3% | -237.7% | ||
| Q1 24 | -11.0% | -405.4% |
每股收益（稀释后）CMCTRGNX
| Q4 25 | $-3.89 | $-1.30 | ||
| Q3 25 | $-23.52 | $-1.20 | ||
| Q2 25 | $-18.94 | $-1.38 | ||
| Q1 25 | $-20.73 | $0.12 | ||
| Q4 24 | $97.71 | $-0.99 | ||
| Q3 24 | $-305.04 | $-1.17 | ||
| Q2 24 | $-98.64 | $-1.05 | ||
| Q1 24 | $-125.46 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $15.4M | $230.1M |
| 总债务越低越好 | $509.8M | — |
| 股东权益账面价值 | $265.4M | $102.7M |
| 总资产 | $859.2M | $453.0M |
| 负债/权益比越低杠杆越低 | 1.92× | — |
8季度趋势，按日历期对齐
现金及短期投资CMCTRGNX
| Q4 25 | $15.4M | $230.1M | ||
| Q3 25 | $17.3M | $274.2M | ||
| Q2 25 | $27.8M | $323.3M | ||
| Q1 25 | $19.8M | $267.9M | ||
| Q4 24 | $20.3M | $234.7M | ||
| Q3 24 | $18.5M | $255.5M | ||
| Q2 24 | $29.3M | $290.4M | ||
| Q1 24 | $21.3M | $338.7M |
总债务CMCTRGNX
| Q4 25 | $509.8M | — | ||
| Q3 25 | $527.8M | — | ||
| Q2 25 | $535.6M | — | ||
| Q1 25 | $512.7M | — | ||
| Q4 24 | $505.7M | — | ||
| Q3 24 | $478.3M | — | ||
| Q2 24 | $485.1M | — | ||
| Q1 24 | $472.8M | — |
股东权益CMCTRGNX
| Q4 25 | $265.4M | $102.7M | ||
| Q3 25 | $281.9M | $161.5M | ||
| Q2 25 | $287.1M | $213.7M | ||
| Q1 25 | $293.0M | $274.2M | ||
| Q4 24 | $304.5M | $259.7M | ||
| Q3 24 | $321.0M | $301.4M | ||
| Q2 24 | $351.1M | $348.3M | ||
| Q1 24 | $369.9M | $390.7M |
总资产CMCTRGNX
| Q4 25 | $859.2M | $453.0M | ||
| Q3 25 | $871.8M | $525.2M | ||
| Q2 25 | $885.0M | $581.0M | ||
| Q1 25 | $882.3M | $490.9M | ||
| Q4 24 | $889.6M | $466.0M | ||
| Q3 24 | $868.0M | $519.1M | ||
| Q2 24 | $891.2M | $569.4M | ||
| Q1 24 | $887.5M | $629.2M |
负债/权益比CMCTRGNX
| Q4 25 | 1.92× | — | ||
| Q3 25 | 1.87× | — | ||
| Q2 25 | 1.87× | — | ||
| Q1 25 | 1.75× | — | ||
| Q4 24 | 1.66× | — | ||
| Q3 24 | 1.49× | — | ||
| Q2 24 | 1.38× | — | ||
| Q1 24 | 1.28× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $5.8M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | — | $-52.8M |
| 自由现金流率自由现金流/营收 | — | -174.0% |
| 资本支出强度资本支出/营收 | — | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | $-126.4M |
8季度趋势，按日历期对齐
经营现金流CMCTRGNX
| Q4 25 | $5.8M | $-52.3M | ||
| Q3 25 | $3.7M | $-56.0M | ||
| Q2 25 | $-2.5M | $-49.3M | ||
| Q1 25 | $1.2M | $33.6M | ||
| Q4 24 | $17.0M | $-31.6M | ||
| Q3 24 | $10.3M | $-40.5M | ||
| Q2 24 | $3.9M | $-45.5M | ||
| Q1 24 | $1.6M | $-55.5M |
自由现金流CMCTRGNX
| Q4 25 | — | $-52.8M | ||
| Q3 25 | — | $-56.5M | ||
| Q2 25 | — | $-49.7M | ||
| Q1 25 | — | $32.6M | ||
| Q4 24 | — | $-32.7M | ||
| Q3 24 | — | $-40.9M | ||
| Q2 24 | — | $-46.0M | ||
| Q1 24 | — | $-56.0M |
自由现金流率CMCTRGNX
| Q4 25 | — | -174.0% | ||
| Q3 25 | — | -189.9% | ||
| Q2 25 | — | -232.8% | ||
| Q1 25 | — | 36.6% | ||
| Q4 24 | — | -154.2% | ||
| Q3 24 | — | -168.9% | ||
| Q2 24 | — | -206.2% | ||
| Q1 24 | — | -358.5% |
资本支出强度CMCTRGNX
| Q4 25 | — | 1.7% | ||
| Q3 25 | — | 1.7% | ||
| Q2 25 | — | 1.8% | ||
| Q1 25 | — | 1.2% | ||
| Q4 24 | — | 5.1% | ||
| Q3 24 | — | 1.3% | ||
| Q2 24 | — | 2.1% | ||
| Q1 24 | — | 3.6% |
现金转化率CMCTRGNX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CMCT
暂无分部数据
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
